CY 2027 CLFS Annual Laboratory Meeting (Part 3 of 4)
Unknown review panel/meeting Ā· July 10, 2026
A clinician presented technical data urging reviewers to reconsider billing/code 0580 for a newer generation of FDA-cleared Lyme disease test kits (ARDA), arguing they use many recombinant antigens, detect multiple Borrelia species, are CDC-accepted for surveillance, and were previously crosswalked incorrectly to older tests.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.